Efficacy of atenolol and captopril in reducing risk of ma
complications in type 2 diabetes: UKPDS 39. UK Prospe

BMJ: British Medical Journal

317, 713-20

Citation Report

#	Article	IF	Citations
1	Diabetes: a time for excitement--and concern. BMJ: British Medical Journal, 1998, 317, 691-692.	2.3	19
2	Combined high blood pressure and glucose in type 2Âdiabetes: double jeopardy. BMJ: British Medical Journal, 1998, 317, 693-694.	2.3	72
3	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology, 1999, 48, 643-648.	2.4	436
5	Controversies surrounding the treatment of the hypertensive patient with diabetes. Current Hypertension Reports, 1999, 1, 512-520.	3.5	9
6	Carcinogenicity of cardiovascular drugs. Current Hypertension Reports, 1999, 1, 212-218.	3.5	17
7	Recent outcome trials of newer antihypertensives. Current Hypertension Reports, 1999, 1, 238-240.	3.5	0
8	Recent clinical trials: A critical appraisal. Current Hypertension Reports, 1999, 1, 333-336.	3.5	4
9	The world health organizationâ€"International society of hypertension blood pressure lowering treatment trialistsâ€™ collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Current Hypertension Reports, 1999, 1, 346-356.	3.5	19
10	Issues of clinical trial design and data interpretations in hypertension. Current Hypertension Reports, 1999, 1, 357-362.	3.5	0
11	Optimal blood pressure on antihypertensive medication. Current Hypertension Reports, 1999, 1, 381-386.	3.5	1
12	Importance of blood pressure reduction for prevention of progression of renal disease. Current Hypertension Reports, 1999, 1, 423-430.	3.5	1
13	Renal Protection and Antihypertensive Drugs. Drugs, 1999, 57, 665-693.	10.9	46
14	Recent advances: Nephrology. BMJ: British Medical Journal, 2000, 320, 98-101.	2.3	16
15	Doxazosin arm of the ALLHAT study discontinued: How equal are antihypertensive drugs?. Current Hypertension Reports, 2000, 2, 241-242.	3.5	4
16	Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. Current Hypertension Reports, 2000, 2, 243-246.	3.5	3
17	Effects of antihypertensive therapy on hypertensive vascular disease. Current Hypertension Reports, 2000, 2, 280-288.	3.5	34
18	Treatment of hypertension in diabetes mellitus. Current Hypertension Reports, 2000, 2, 335-342.	3.5	8
19	Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents. Current Hypertension Reports, 2000, 2, 525-529.	3.5	5

#	Article	IF	Citations
20	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ: British Medical Journal, 2000, 321, 412-419.	2.3	1,737
21	Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus. Drugs and Aging, 2000, 17, 463-476.	2.7	12
22	Implications of the UK Prospective Diabetes Study. Drugs and Aging, 2000, 16, 159-164.	2.7	18
23	Irbesartan. Drugs, 2000, 59, 1187-1206.	10.9	39
24	Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. Drugs, 2000, 60, 975-983.	10.9	41
25	Drug-Induced Lipid Changes. Drug Safety, 2001, 24, 443-456.	3.2	100
26	??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. Drugs, 2001, 61, 429-435.	10.9	7
27	Management of High-Risk Hypertensive Patients with Diabetes: Potential Role of Angiotensin II Receptor Antagonists. Journal of Clinical Hypertension, 2001, 3, 225-235.	2.0	3
28	Evidence based management of hypertension: What are the elements of good treatment for hypertension?. BMJ: British Medical Journal, 2001, 322, 1107-1109.	2.3	22
29	Treatment of coexisting diabetes and hypertension. Current Cardiology Reports, 2001, 3, 498-503.	2.9	3
30	The role of angiotensinconverting enzyme inhibitors in the treatment of hypertension. Current Cardiology Reports, 2001, 3, 511-518.	2.9	8
31	Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports, 2001, 1, 133-139.	4.2	5
32	Treatment of hypertension in diabetic patients with nephropathy. Current Diabetes Reports, 2001, 1, 251-260.	4.2	6
33	Problems in the control of systolic blood pressure. Current Hypertension Reports, 2001, 3, 173-174.	3.5	0
34	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. Current Hypertension Reports, 2001, 3, 422-428.	3.5	11
35	Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes. Current Hypertension Reports, 2001, 3, 340-349.	3.5	4
36	Oral antidiabetic treatment in patients with coronary disease: Timeâ€related increased mortality on combined glyburide/metformin therapy over a 7.7â€year followâ€up. Clinical Cardiology, 2001, 24, 151-158.	1.8	103
37	Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. , 2001, 4, 269-279.		2

#	Article	IF	Citations
38	Factors Influencing the Systolic Blood Pressure Response to Drug Therapy. Journal of Clinical Hypertension, 2002, 4, 35-40.	2.0	20
39	Should Î² Blockers Be Used in the Treatment of Hypertension in the Elderly?. Journal of Clinical Hypertension, 2002, 4, 286-294.	2.0	7
40	Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. Journal of Clinical Hypertension, 2002, 4, 11-31.	2.0	5
41	ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?. Journal of Clinical Hypertension, 2002, 4, 420-440.	2.0	30
42	Update on the Management of Diabetes and Hypertension. Journal of Clinical Hypertension, 2002, 4, 3-10.	2.0	9
43	Quinapril. Drugs, 2002, 62, 339-385.	10.9	15
44	The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications. Drugs, 2002, 62, 2007-2012.	10.9	13
45	Prevention of heart failure. Current Cardiology Reports, 2002, 4, 194-199.	2.9	7
46	The use of ACE inhibitors on diabetic patients without renal disease. Current Diabetes Reports, 2002, 2, 21-25.	4.2	2
47	Cardiovascular risk factors in diabetic patients with hypertension. Current Diabetes Reports, 2002, 2, 263-266.	4.2	2
48	The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports, 2002, 2, 423-430.	4.2	0
49	Blood pressure controlâ€"Effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports, 2002, 2, 530-538.	4.2	5
50	Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports, 2002, 4, 185-190.	3.5	17
51	Carcinogenicity of antihypertensive therapy. Current Hypertension Reports, 2002, 4, 195-201.	3.5	24
52	Sympathetic nervous system function in renal hypertension. Current Hypertension Reports, 2002, 4, 229-236.	3.5	22
53	Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease. Current Hypertension Reports, 2002, 4, 445-452.	3.5	5
54	Managing the hypertensive patient with ischemic heart disease. Current Hypertension Reports, 2002, 4, 350-357.	3.5	0
55	Optimizing blood pressure control in the obese patient. Current Hypertension Reports, 2002, 4, 358-362.	3.5	5

#	Article	IF	Citations
56	Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Current Hypertension Reports, 2002, 4, 387-393.	3.5	42
57	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. Current Hypertension Reports, 2002, 4, 290-297.	3.5	1
58	The Cost of Diabetes Type II in Europe The CODE-2 Study. Diabetologia, 2002, 45, S1-S4.	6.3	97
60	Use of ACE inhibitors for secondary prevention. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 51-61.	0.9	1
61	The J-curve in hypertension. Current Cardiology Reports, 2003, 5, 441-452.	2.9	34
62	Proteinuria in diabetic nephropathy: Treatment and evolution. Current Diabetes Reports, 2003, 3, 497-504.	4.2	28
63	Are low target blood pressure goals justified in persons with diabetes mellitus?. Current Hypertension Reports, 2003, 5, 231-238.	3.5	3
64	Lessons from trials in hypertensive type 2 diabetic patients. Current Hypertension Reports, 2003, 5, 322-328.	3.5	1
65	Angiotensin II and the glomerulus: Focus on diabetic kidney disease. Current Hypertension Reports, 2003, 5, 172-180.	3.5	5
66	Isolated systolic hypertension and the risk of vascular disease. Current Hypertension Reports, 2003, 5, 372-379.	3.5	18
68	Under-prescribing of cardiovascular therapies for diabetes in primary care. European Journal of Clinical Pharmacology, 2003, 58, 835-841.	1.9	26
69	Variation in diabetes care by age: opportunities for customization of care. BMC Family Practice, 2003, 4, 16.	2.9	28
71	Treatment of Lupus Nephritis. Drugs, 2003, 63, 257-274.	10.9	12
72	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. Drugs, 2003, 63, 1165-1184.	10.9	76
73	The Differences Between ACE Inhibitor-Treated and Calcium Channel Blocker-Treated Hypertensive Patients. Journal of Clinical Hypertension, 2003, 5, 337-344.	2.0	2
74	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. Journal of Clinical Hypertension, 2003, 5, 66-75.	2.0	26
75	Meeting the Challenge to Improve the Treatment of Hypertension in Blacks. Journal of Clinical Hypertension, 2003, 5, 393-401.	2.0	17
76	Response to Six Classes of Antihypertensive Medications by Body Mass Index in a Randomized Controlled Trial. Journal of Clinical Hypertension, 2003, 5, 197-201.	2.0	8

#	Article	IF	Citations
77	Hypertension in the Metabolic Syndrome and Diabetes: Pathogenesis, Clinical Studies, and Treatment. Journal of Clinical Hypertension, 2003, 5, 3-10.	2.0	9
78	Prevention and Treatment of Diabetic Nephropathy in Older Patients. Drugs and Aging, 2003, 20, 419-435.	2.7	2
79	??-Blockers after Acute Myocardial Infarction in Elderly Patients with Diabetes Mellitus. Drugs and Aging, 2003, 20, 13-22.	2.7	7
80	The Diabetes Prevention Program and Its Global Implications. Journal of the American Society of Nephrology: JASN, 2003, 14, S103-S107.	6.1	46
81	What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ: British Medical Journal, 2003, 327, 266-0.	2.3	63
82	The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clinical Trials, 2004, 1, 532-544.	1.6	54
83	Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team â€“ a pilot study. International Journal of Clinical Pharmacy, 2004, 26, 18-25.	1.4	60
84	Angiotensin AT 1 receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodiliation in normotensive diabetic rats. Diabetologia, 2004, 47, 113-123.	6.3	72
85	Antihypertensive drugs and the kidney. Current Cardiology Reports, 2004, 6, 403-408.	2.9	4
86	Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Current Hypertension Reports, 2004, 6, 215-223.	3.5	99
87	A novel approach to treatment of hypertension in diabetic patients â€“ a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 â€“ rationale and design [ISRCTN55725285]. Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 9.	1.5	6
88	Cost-Effective Strategies in the Prevention of Diabetic Nephropathy. Pharmacoeconomics, 2004, 22, 9-28.	3.3	24
89	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. Pharmacoeconomics, 2004, 22, 321-341.	3.3	25
90	Slowing the Progression of Adult Chronic Kidney Disease. Drugs, 2004, 64, 2273-2289.	10.9	27
91	Hypoglycaemia in Elderly Patients with Diabetes Mellitus. Drugs and Aging, 2004, 21, 511-530.	2.7	137
92	Cardiovascular Safety of ??2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease. Drugs and Aging, 2004, 21, 405-414.	2.7	70
93	Antihypertensive Medications and Weight Gain. Journal of Clinical Hypertension, 2004, 6, 90-90.	2.0	6
94	The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia, 2005, 48, 1439-1444.	6.3	84

#	Article	IF	Citations
95	Prevention of coronary heart disease in diabetes. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 259-271.	0.9	3
96	Clinical Trials Report. Current Hypertension Reports, 2005, 7, 204-205.	3.5	2
97	Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. Current Hypertension Reports, 2005, 7, 439-449.	3.5	8
98	Does ALLHAT change the management of hypertension in chronic kidney disease?. Current Hypertension Reports, 2005, 7, 474-483.	3.5	5
99	Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention. Current Hypertension Reports, 2005, 7, 367-373.	3.5	4
100	BENEDICT in the treatment of hypertension. Current Hypertension Reports, 2005, 7, 121-123.	3.5	5
101	Prevention of Nephropathy in Patients with type 2 Diabetes Mellitus. International Urology and Nephrology, 2005, 37, 655-663.	1.4	8
102	GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions. BMC Family Practice, 2005, 6, 20.	2.9	137
103	Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart, 2005, 91, 451-455.	2.9	14
104	Early Initiation of Î² Blockade in Heart Failure: Issues and Evidence. Journal of Clinical Hypertension, 2005, 7, 520-528.	2.0	10
105	Treatment of Diabetic Hypertensive Patients: Results of a National Survey. Journal of Clinical Hypertension, 2005, 7, 110-110.	2.0	0
106	Cardioprotection: The Role of Î²â€Blocker Therapy. Journal of Clinical Hypertension, 2005, 7, 409-416.	2.0	34
107	Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus. Drugs, 2005, 65, 433-445.	10.9	8
108	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. Pharmacoeconomics, 2006, 24, 425-441.	3.3	42
109	Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease. Drugs, 2006, 66, 2213-2234.	10.9	36
110	Do the Metabolic Effects of ? Blockers Make Them Leading or Supporting Antihypertensive Agents in the Treatment of Hypertension?. Journal of Clinical Hypertension, 2006, 8, 351-356.	2.0	21
111	Challenges and Risks in Attaining the Systolic Blood Pressure Goal of <130 mm Hg in All Diabetic Patients. Journal of Clinical Hypertension, 2006, 8, 50-52.	2.0	1
112	Hypertensionâ€"A Treatable Component of the Cardiometabolic Syndrome: Challenges for the Primary Care Physician. Journal of Clinical Hypertension, 2006, 8, 12-20.	2.0	7

#	Article	IF	Citations
113	Review Paper ï¿½ CME. Insulin Resistance, Diabetes, Hypertension, and Renin?Angiotensin System Inhibition: Reducing Risk for Cardiovascular Disease. Journal of Clinical Hypertension, 2006, 8, 713-722.	2.0	35
114	Antihypertensive Prescribing Practices: Impact of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension, 2006, 8, 860-864.	2.0	13
115	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia, 2006, 49, 1761-1769.	6.3	303
117	Modifications of Coronary Risk Factors. American Journal of Cardiology, 2006, 97, 41-52.	1.6	17
118	Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). BMC Cardiovascular Disorders, 2006, 6, 39.	1.7	5
119	Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall. BMC Health Services Research, 2006, 6, 47.	2.2	17
120	Re-examining the efficacy of Â-blockers for the treatment of hypertension: a meta-analysis. Cmaj, 2006, 174, 1737-1742.	2.0	179
121	Use of Chronic Care Model Elements Is Associated With Higher-Quality Care for Diabetes. Annals of Family Medicine, 2007, 5, 14-20.	1.9	143
122	How Evidence-Based Are the Recommendations in Evidence-Based Guidelines?. PLoS Medicine, 2007, 4, e250.	8.4	199
123	Direct Renin Inhibitors: A New Approach to Antihypertensive Drug Treatment. Journal of Clinical Hypertension, 2007, 9, 615-621.	2.0	2
124	ACE Inhibitors and ARBs: Are They Better Than Other Agents to Slow Nephropathy Progression?. Journal of Clinical Hypertension, 2007, 9, 413-415.	2.0	4
125	Hypertension Treatment Guidelines: Is It Time for an Update?. Journal of Clinical Hypertension, 2007, 9, 9-14.	2.0	9
126	Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart, 2007, 93, 968-973.	2.9	135
127	Imidapril. Drugs, 2007, 67, 1379-1382.	10.9	2
128	The Role of Sulodexide in the Treatment of Diabetic Nephropathy. Drugs, 2007, 67, 2681-2696.	10.9	41
129	The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes and hypertension in Ontario, Canada. Implementation Science, 2007, 2, 37.	6.9	18
131	Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update. Current Diabetes Reports, 2007, 7, 208-217.	4.2	13
132	Beta-blocker contraindications: Are there patients or situations where use is inappropriate?. Current Heart Failure Reports, 2007, 4, 93-98.	3.3	1

#	Article	IF	Citations
133	Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure. Current Heart Failure Reports, 2007, 4, 99-102.	3.3	4
134	ADVANCE in management of vascular complications of diabetes. Current Hypertension Reports, 2008, 10, 255-257.	3.5	0
135	RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clinical Research in Cardiology, 2008, 97, 418-431.	3.3	135
136	Retinal ganglion cells in diabetes. Journal of Physiology, 2008, 586, 4401-4408.	2.9	341
137	The Metabolic Syndrome. Endocrine Reviews, 2008, 29, 777-822.	20.1	1,513
138	Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Canadian Journal of Cardiology, 2008, 24, 491-496.	1.7	50
139	An Appreciation of Robert Turner. Diabetes, 2008, 57, 2918-2921.	0.6	2
140	Early detection and management of the high-risk patient with elevated blood pressure. Vascular Health and Risk Management, 2008, Volume 4, 289-296.	2.3	27
141	Simultaneous transdermal extraction of glucose and lactate from human subjects by reverse iontophoresis. International Journal of Nanomedicine, 2008, 3, 211.	6.7	16
142	Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage. Diabetes, 2009, 58, 215-226.	0.6	188
143	Perioperative Blood Glucose Monitoring in the General Surgical Population. Journal of Diabetes Science and Technology, 2009, 3, 1282-1287.	2.2	22
144	Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care, 2009, 32, 1556-1562.	8.6	124
145	(Pro)renin Receptorâ€“Mediated Signal Transduction and Tissue Renin-Angiotensin System Contribute to Diabetes-Induced Retinal Inflammation. Diabetes, 2009, 58, 1625-1633.	0.6	136
146	A Summary of the ADVANCE Trial. Diabetes Care, 2009, 32, S357-S361.	8.6	88
147	Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Review of Cardiovascular Therapy, 2009, 7, 689-702.	1.5	28
148	Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. Journal of Clinical Hypertension, 2009, 11, 636-643.	2.0	30
149	Evidence-based Practice Guideline for the Treatment of CKD. Clinical and Experimental Nephrology, 2009, 13, 537-566.	1.6	106
150	An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. Irish Journal of Medical Science, 2009, 178, 179-186.	1.5	14

#	Article	IF	Citations
151	Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials. Current Diabetes Reports, 2009, 9, 229-237.	4.2	10
152	Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 2009, 6, 126-132.	3.3	3
153	Update on the metabolic syndrome: Hypertension. Current Hypertension Reports, 2009, 11, 150-155.	3.5	18
154	Choosing the ideal drug for hypertension after ischemic stroke. Current Hypertension Reports, 2009, 11, 246-252.	3.5	2
156	Barriers and facilitators to evidence based care of type 2 diabetes patients: experiences of general practitioners participating to a quality improvement program. Implementation Science, 2009, 4, 41.	6.9	42
157	The sweeter side of ACE2: Physiological evidence for a role in diabetes. Molecular and Cellular Endocrinology, 2009, 302, 193-202.	3.2	183
158	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers. American Heart Journal, 2009, 157, 334.e1-334.e8.	2.7	25
160	Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged â‰¥65 Years. Drugs and Aging, 2009, 26, 751-767.	2.7	15
161	Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology, 2009, 256, 1603-1619.	3.6	47
162	Early Age-Related Macular Degeneration Impairs Tolerance to Stimulus Degradation. Optometry and Vision Science, 2010, 87, 532-542.	1.2	7
164	Evidence for Aggressive Blood Pressureâ€“Lowering Goals in Patients with Coronary Artery Disease. Current Atherosclerosis Reports, 2010, 12, 134-139.	4.8	10
165	Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity. Current Diabetes Reports, 2010, 10, 139-144.	4.2	25
166	From design to implementation - The Joint Asia Diabetes Evaluation (JADE) program: A descriptive report of an electronic web-based diabetes management program. BMC Medical Informatics and Decision Making, 2010, 10, 26.	3.0	46
167	Is There Accord in ACCORD? Lower Blood Pressure Targets in Type 2 Diabetes Does Not Lead to Fewer Cardiovascular Events Except for Reductions in Stroke. Journal of Clinical Hypertension, 2010, 12, 472-477.	2.0	5
168	Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovascular Diabetology, 2010, 9, 1.	6.8	38
169	Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection. Vascular Health and Risk Management, 2010, 6, 479.	2.3	5
170	Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vascular Health and Risk Management, 2010, 6, 883.	2.3	167
171	Diabetic Retinopathy. Deutsches Ärzteblatt International, 2010, 107, 75-83; quiz 84.	0.9	137

#	Article	IF	Citations
172	Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk. International Journal of Hypertension, 2010, 2010, 1-8.	1.3	7
173	Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence. Vascular Health and Risk Management, 2010, 6, 363.	2.3	12
174	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2010, 362, 1575-1585.	27.0	3,117
175	ACE-Inhibition and Physical Function: Results From the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) Study. Journal of the American Medical Directors Association, 2010, 11, 26-32.	2.5	61
176	Effect of systemic medications on onset and progression of diabetic retinopathy. Nature Reviews Endocrinology, 2010, 6, 494-508.	9.6	42
177	Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology, 2010, 55, 283-293.	2.8	174
178	Insufficient control of morning home blood pressure in Japanese patients with hypertension associated with diabetes mellitus. Journal of Diabetes Investigation, 2010, 1, 266-272.	2.4	1
179	ArtistÂ® Tablets (Carvedilol) for Hypertensive Patients in Japan. Drugs in R and D, 2011, 11, 191-205.	2.2	2
180	Blood Pressure Targets in Diabetes: Is This the Time for Change?â€"CON (Rebuttal). Journal of Clinical Hypertension, 2011, 13, 268-269.	2.0	1
181	Thiazide Diuretics and Î²â€Blockers in the Treatment of Hypertension in Diabetes Mellitus. Journal of Clinical Hypertension, 2011, 13, 296-300.	2.0	11
182	Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia, 2011, 54, 2724-2735.	6.3	31
183	Should Î² Blockers No Longer Be Considered First-line Therapy for the Treatment of Essential Hypertension Without Comorbidities?. Current Cardiology Reports, 2011, 13, 507-516.	2.9	20
184	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovascular Diabetology, 2011, 10, 22.	6.8	137
185	Can we bridge the gap? Knowledge and practices related to Diabetes Mellitus among general practitioners in a developing country: A cross sectional study. Asia Pacific Family Medicine, 2011, 10, 15.	0.4	9
186	Medical Complications of Obesity and Optimization of the Obese Patient for Colorectal Surgery. Clinics in Colon and Rectal Surgery, 2011, 24, 211-221.	1.1	6
187	Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 17-26.	3.2	28
188	Primary Prevention of Heart Failure. ISRN Cardiology, 2012, 2012, 1-15.	1.6	18
189	Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. International Journal of Hypertension, 2012, 2012, 1-9.	1.3	26

#	Article	IF	Citations
190	Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ, The, 2012, 345, e5567-e5567.	6.0	76
191	The Effect of Antihypertensive Drugs on Endothelial Function as Assessed by Flow-Mediated Vasodilation in Hypertensive Patients. International Journal of Vascular Medicine, 2012, 2012, 1-11.	1.0	19
192	Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes. Diabetes, 2012, 61, 3026-3032.	0.6	12
193	Thiazolidinedioneâ€independent activation of peroxisome proliferatorâ€activated receptor Î³ is a potential target for diabetic macrovascular complications. Journal of Diabetes Investigation, 2012, 3, 11-23.	2.4	2
194	Consistency with the Dietary Approaches to Stop Hypertension Diet among Adults with Diabetes. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 1798-1805.	0.8	6
195	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International, 2012, 81, 586-594.	5.2	53
196	Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertension Research, 2012, 35, 4-16.	2.7	159
197	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. Journal of General Internal Medicine, 2012, 27, 458-468.	2.6	46
198	Reno-protective effects of reninâ€“angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia, 2012, 55, 566-578.	6.3	118
199	Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?. Current Diabetes Reports, 2013, 13, 350-361.	4.2	28
200	Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension. Drugs in R and D, 2013, 13, 63-73.	2.2	18
201	Blood Pressure Control and Primary Prevention of Stroke: Summary of the Recent Clinical Trial Data and Meta-Analyses. Current Hypertension Reports, 2013, 15, 559-574.	3.5	78
202	Treatment Strategies for the Prevention of Heart Failure. Current Heart Failure Reports, 2013, 10, 331-340.	3.3	9
203	The past, present and future of reninâ€“angiotensin aldosterone system inhibition. International Journal of Cardiology, 2013, 167, 1677-1687.	1.7	97
204	The Lower, the Better?. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 135-138.	2.2	2
205	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, The, 2013, 347, f5680-f5680.	6.0	209
206	Hypertension Management in the High Cardiovascular Risk Population. International Journal of Hypertension, 2013, 2013, 1-7.	1.3	11
207	Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiology, 2013, 2013, 1-8.	1.6	28

#	Article	IF	Citations
208	Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes. Diabetes Care, 2013, 36, 322-327.	8.6	20
209	Cardinal Role of the Intrarenal Renin-Angiotensin System in the Pathogenesis of Diabetic Nephropathy. Journal of Investigative Medicine, 2013, 61, 256-264.	1.6	53
210	Design, implementation, and evaluation of a pediatric and adolescent type 2 diabetes management program at a tertiary pediatric center. Journal of Multidisciplinary Healthcare, 2014, 7, 321.	2.7	7
211	Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovascular Disorders, 2014, 14, 148.	1.7	36
212	Lifestyle Factors in Hypertension Drug Research: Systematic Analysis of Articles in a Leading Cochrane Report. International Journal of Hypertension, 2014, 2014, 1-10.	1.3	11
213	Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease. International Journal of Hypertension, 2014, 2014, 1-7.	1.3	24
214	Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. BMC Cardiovascular Disorders, 2014, 14, 4.	1.7	12
215	The Glycemic Effects of Antihypertensive Medications. Current Hypertension Reports, 2014, 16, 410.	3.5	14
216	The effect of RAAS blockade on the progression of diabetic nephropathy. Nature Reviews Nephrology, 2014, 10, 77-87.	9.6	128
217	New Hypertension Guidelines: A View from Latin America. Journal of Clinical Hypertension, 2014, 16, 261-262.	2.0	0
218	Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats. Diabetology and Metabolic Syndrome, 2014, 6, 57.	2.7	17
219	Prescription medication burden in patients with newly diagnosed diabetes: A SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 374-382.	1.5	24
220	Survival on Dialysis Among American Indians and Alaska Natives With Diabetes in the United States, 1995â€“2010. American Journal of Public Health, 2014, 104, S490-S495.	2.7	13
221	Feasibility and impact of implementing a private care systemâ€™s diabetes quality improvement intervention in the safety net: a cluster-randomized trial. Implementation Science, 2015, 10, 83.	6.9	17
222	Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. Journal of Clinical Medicine, 2015, 4, 1908-1937.	2.4	40
223	Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review. Current Medicinal Chemistry, 2015, 22, 2580-2589.	2.4	23
224	Diabetic retinopathy - ocular complications of diabetes mellitus. World Journal of Diabetes, 2015, 6, 489.	3.5	351
225	Diabetic retinopathy and systemic factors. Middle East African Journal of Ophthalmology, 2015, 22, 151.	0.3	60

#	Article	IF	Citations
226	Effectiveness of Prior Use of Beta-Blockers for Preventing Adverse Influences of Severe Hypoglycemia in Patients With Diabetes. Medicine (United States), 2015, 94, e1629.	1.0	13
227	Blood pressure control for diabetic retinopathy. The Cochrane Library, 2015, 1, CD006127.	2.8	91
228	Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. Age and Ageing, 2015, 44, 566-573.	1.6	17
229	Timeline of History of Hypertension Treatment. Frontiers in Cardiovascular Medicine, 2016, 3, 3.	2.4	65
230	Cardiovascular and Renal Outcomes of Reninâ€“Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Medicine, 2016, 13, e1001971.	8.4	75
231	Peripheral vasoconstriction induced by Î²â€adrenoceptor blockers: a systematic review and a network metaâ€analysis. British Journal of Clinical Pharmacology, 2016, 82, 549-560.	2.4	19
232	Several Aspects of Internet and Web-Based Technology in Diabetes Management. Diabetes Spectrum, 2016, 29, 245-248.	1.0	3
233	Novel insight into the dangerous connection between diabetes and heart failure. Herz, 2016, 41, 201-207.	1.1	12
234	Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ, The, 2016, 352, i438.	6.0	135
235	Adjusting the 17Î²â€“Estradiol-to-Androgen Ratio Ameliorates Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 3035-3050.	6.1	30
236	Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, The, 2016, 352, i717.	6.0	288
237	Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial. International Ophthalmology, 2016, 36, 225-235.	1.4	2
238	Blood pressure control in type 2 diabetic patients. Cardiovascular Diabetology, 2017, 16, 3.	6.8	77
239	Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. Journal of Diabetes Investigation, 2017, 8, 261-271.	2.4	37
240	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	2.8	205
241	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nature Reviews Endocrinology, 2017, 13, 365-374.	9.6	29
242	Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 8-16.	0.8	109
243	Blood pressure management in patients with type 2 diabetes mellitus. Hypertension Research, 2017, 40, 721-729.	2.7	7

#	Article	IF	Citations
244	Risk of Cardiovascular Events in Patients With Diabetes Mellitus on Î²-Blockers. Hypertension, 2017, 70, 103-110.	2.7	61
245	The Real Role of Î²-Blockers in Daily Cardiovascular Therapy. American Journal of Cardiovascular Drugs, 2017, 17, 361-373.	2.2	79
246	Managing Hypertension in Patients Aged 75ÂYears and Older. Current Hypertension Reports, 2017, 19, 88.	3.5	4
247	Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada. BMJ Open, 2017, 7, e013808.	1.9	7
248	Managing Hypertension in the Elderly: What is Different, What is the Same?. Current Hypertension Reports, 2017, 19, 67.	3.5	5
249	Pharmacotherapy for hypertension in adults aged 18 to 59 years. The Cochrane Library, 2017, 2017, CD008276.	2.8	32
250	Mechanistic Insights into Pathological Changes in the Diabetic Retina. American Journal of Pathology, 2017, 187, 9-19.	3.8	157
251	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. International Journal of Chronic Diseases, 2017, 2017, 1-11.	1.0	1
252	Hypertension and blood pressure variability management practices among physicians in Singapore. Vascular Health and Risk Management, 2017, Volume 13, 275-285.	2.3	14
253	Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy. Diabetes and Metabolism Journal, 2017, 41, 128.	4.7	43
254	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. American Journal of Kidney Diseases, 2018, 72, 728-744.	1.9	58
255	Updates to Adherence to Hypertension Medications. Current Hypertension Reports, 2018, 20, 34.	3.5	19
256	Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease. Pharmacotherapy, 2018, 38, 309-318.	2.6	35
257	First-line reninâ€“angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus. Journal of Human Hypertension, 2018, 32, 494-506.	2.2	9
258	First-line drugs for hypertension. The Cochrane Library, 2018, 2018, CD001841.	2.8	197
259	Switching from lowâ€dose thiazide diuretics to sodiumâ€“glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. Journal of Diabetes Investigation, 2018, 9, 875-881.	2.4	15
260	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 2018, 9, CD011798.	2.8	48
261	Hypertension Management in Diabetes: 2018 Update. Diabetes Spectrum, 2018, 31, 218-224.	1.0	51

#	Article	IF	Citations
262	Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. PLoS ONE, 2018, 13, e0195898.	2.5	25
263	The impact of insulin pump therapy to oxidative stress in patients with diabetic nephropathy. European Journal of Medical Research, 2018, 23, 7.	2.2	14
264	Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 427-438.	2.4	57
265	Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project. Diabetes Therapy, 2019, 10, 1099-1111.	2.5	4
266	Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Current Cardiology Reports, 2019, 21, 21.	2.9	363
267	Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol. BMJ Open, 2019, 9, e033504.	1.9	10
268	Effect of Renin-Angiotensin System Blockade on Mortality in Korean Hypertensive Patients with Proteinuria. Electrolyte and Blood Pressure, 2019, 17, 25.	1.8	2
269	Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle. Cardiovascular Research, 2019, 115, 590-601.	3.8	8
270	Pharmacotherapy for hypertension in adults 60 years or older. The Cochrane Library, 2020, 2020, CD000028.	2.8	26
271	Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 13.	1.0	7
272	Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Diseases (Basel, Switzerland), 2020, 6, 215-225.	2.5	98
273	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	2.4	159
274	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	1.4	266
275	Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. Journal of Clinical Hypertension, 2020, 22, 2084-2092.	2.0	3
276	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	27.0	228
277	Effect of a nurse-led lifestyle choice and coaching intervention on systolic blood pressure among type 2 diabetic patients with a high atherosclerotic cardiovascular risk: study protocol for a cluster-randomized trial. Trials, 2021, 22, 133.	1.6	1
278	System Architecture for "Support Through Mobile Messaging and Digital Health Technology for Diabetes" (SuMMiT-D): Design and Performance in Pilot and Randomized Controlled Feasibility Studies. JMIR Formative Research, 2021, 5, e18460.	1.4	4
279	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. Annals of Translational Medicine, 2021, 9, 716-716.	1.7	5

#	Article	IF	Citations
280	Islet microangiopathy and augmented Î² cell loss in Japanese nonobese type 2 diabetes patients who died of acute myocardial infarction. Journal of Diabetes Investigation, 2021, 12, 2149.	2.4	4
281	Effect of Third-Generation Beta Blockers on Weight Loss in a Population of Overweight-Obese Subjects in a Controlled Dietary Regimen. Journal of Nutrition and Metabolism, 2021, 2021, 1-7.	1.8	7
282	Laparoscopic sleeve gastrectomy in the treatment of gastrointestinal stroma tumours in morbid obese patients. BMJ Case Reports, 2009, 2009, bcr0620080204-bcr0620080204.	0.5	9
283	Associations between multimorbidity and glycaemia (HbA1c) in people with type 2 diabetes: cross-sectional study in Australian general practice. BMJ Open, 2020, 10, e039625.	1.9	8
284	Beneficial effects of statins on the kidney. Journal of Clinical Pathology, 2004, 57, 673-4.	2.0	7
285	Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial. PLoS ONE, 2015, 10, e0125519.	2.5	8
286	The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease. PLoS ONE, 2017, 12, e0170874.	2.5	24
287	The Incidence of Microalbuminuria and its Associated Risk Factors in Type 2 Diabetic Patients in Isfahan, Iran. Review of Diabetic Studies, 2007, 4, 242-248.	1.3	13
288	Blood pressure targets for hypertension in patients with type 2 diabetes. Annals of Translational Medicine, 2018, 6, 199-199.	1.7	9
290	Does tight control of systemic factors help in the management ofdiabetic retinopathy?. Indian Journal of Ophthalmology, 2016, 64, 62.	1.1	19
291	Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population. Advanced Biomedical Research, 2016, 5, 82.	0.5	7
292	Vitreous rebleed following sutureless vitrectomy: Incidence and risk factors. Indian Journal of Ophthalmology, 2018, 66, 558.	1.1	8
293	CapÃtulo 7 â€“ Tratamento Medicamentoso. Arquivos Brasileiros De Cardiologia, 2016, 107, 35-43.	0.8	9
294	Attenuated levels of pro-inflammatory markers in diabetic retinopathy patients undergoing treatment with antihyperglycemic and antihypertensive drugs. Clinics, 2013, 68, 185-191.	1.5	14
295	Targeting the renin-angiotensin system in patients with renal disease. Journal of the Royal Society of Medicine, 2002, 95, 391-397.	2.0	0
296	Treating type 2Âdiabetes. BMJ: British Medical Journal, 1999, 318, 666-666.	2.3	0
297	Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication. Cardiovascular Endocrinology and Metabolism, 2021, 10, 31-36.	1.1	2
298	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ: British Medical Journal, 1998, 317, 703-13.	2.3	1,610

#	Article	IF	Citations
299	Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. Cmaj, 2000, 163, 188-92.	2.0	12
300	Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme inhibitors. Cmaj, 2000, 163, 293-6.	2.0	5
301	Microalbuminuria in diabetes mellitus. Cmaj, 2002, 167, 499-503.	2.0	7
302	The cost of major comorbidity in people with diabetes mellitus. Cmaj, 2003, 168, 1661-7.	2.0	36
303	Glycaemia and vascular effects of type 2 diabetes. Lowering glucose concentrations may not be of any value in itself. BMJ: British Medical Journal, 2001, 322, 1245-6; author reply 1247.	2.3	0
304	Metabolic syndrome and type 2 diabetes: the Hong Kong perspective. Clinical Biochemist Reviews, 2005, 26, 51-7.	3.3	4
305	The accuracy of digital-video retinal imaging to screen for diabetic retinopathy: an analysis of two digital-video retinal imaging systems using standard stereoscopic seven-field photography and dilated clinical examination as reference standards. Transactions of the American Ophthalmological Society, 2004, 102, 321-40.	1.4	27
306	Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. Vascular Health and Risk Management, 2007, 3, 165-71.	2.3	5
307	Cardiac and vascular protection: the potential of ONTARGET. Medscape Journal of Medicine, 2008, 10 Suppl, S7.	0.6	1
308	Diabetic retinopathy: an update. Indian Journal of Ophthalmology, 2008, 56, 178-88.	1.1	35
309	Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clinical Ophthalmology, 2007, 1, 383-91.	1.8	21
310	Diabetes: treating hypertension. Clinical Evidence, 2009, 2009, .	0.2	0
311	Diabetes: treating hypertension. Clinical Evidence, 2012, 2012, .	0.2	0
312	Management of Diabetic Nephropathy in the Elderly: Special Considerations. Journal of Nephrology & Therapeutics, 2012, 2, .	0.1	1
313	A look at the trend in diabetes-related complications in the U.S. over the past two decades: looking ahead. Annals of Translational Medicine, 2014, 2, 121.	1.7	2
314	ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH. European Medical Journal Diabetes, 2017, 5, 84-92.	4.0	10
315	Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e32918.	1.0	1
316	Cardiovascular therapeutics: A new potential for anxiety treatment?. Medicinal Research Reviews, 2022, 42, 1202-1245.	10.5	10

#	Article	IF	Citations
317	Effects of antihypertensive treatments on incidence of diabetes: a case-control study. Journal of Endocrinological Investigation, 2012, 35, 135-8.	3.3	3
319	Combination therapy with artemether and enalapril improves type 1 diabetic nephropathy through enhancing antioxidant defense.. American Journal of Translational Research (discontinued), 2022, 14, 211-222.	0.0	0